Exemestane
Small molecule targets CYP19A1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | AROMASIN | — | 2005-10-05 – 2016-07-25 | fda.gov ↗ |
| Approved | US (FDA) | AROMASIN | — | 1999-10-21 | fda.gov ↗ |
Trials 169 · started per year
Also used as a comparator or background therapy in 151 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04088032 Background | Oct 2019 → Dec 2020 | female breast carcinoma, hormone receptor-positive breast cancer | Alison Stopeck | Withdrawn | No outcome recorded |
| Phase 113 trials | ||||||
| Phase 1 | NCT06218303 Background | Feb 2024 → Aug 2026 overdue | ductal breast carcinoma in situ | Finn, Olivera, PhD | Recruiting | No outcome recorded |
| Phase 1 | NCT05307705 Background | May 2022 → Dec 2026 expected | breast cancer | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT04572295 Background | Oct 2020 → Jun 2026 | breast neoplasm | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03846583 Background | Jun → Sep 2020 | breast cancer | Dana-Farber Cancer Institute | Withdrawn | No outcome recorded |
| Phase 1 | NCT02820961 Comparator | Jun 2016 → Sep 2018 | estrogen-receptor positive breast cancer | Syndax Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02623751 Background | Nov 2015 → Oct 2020 | breast cancer | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02392611 Background | Mar 2015 → Oct 2017 | lymphoma | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT02123823 Background | May 2014 → Nov 2016 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01938846 Background | Sep 2013 → Jul 2016 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01594398 Background | May 2012 → Apr 2014 | estrogen-receptor positive breast cancer, non-small cell lung carcinoma | Syndax Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01597193 Background | Apr 2012 → Dec 2015 | female breast carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00508586 Background | Nov 2007 → Mar 2012 | breast cancer | PTC Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01240928 Background | — | breast cancer | Vanderbilt-Ingram Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT07596212 Background | Jul 2026 → Jul 2028 expected | hormone receptor-positive breast cancer, hypoactive sexual desire disorder | University of Illinois at Chicago | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07708194 Background | Jun 2025 → Feb 2027 expected | HER2 positive breast carcinoma, hormone receptor-positive breast cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05768139 Background | Apr 2023 → Jul 2030 expected | breast cancer | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05573126 Background | Jan 2023 → Feb 2028 expected | hormone receptor-positive breast cancer | Ellipses Pharma | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02983604 Background | Jan 2017 → Jul 2018 | estrogen-receptor positive breast cancer | Gilead Sciences | Terminated | No outcome recorded |
| Phase 1/2 | NCT01202591 Background | Dec 2010 → Sep 2014 | estrogen-receptor positive breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 267 trials | ||||||
| Phase 2 | NCT07610720 Background | Jun 2026 → Nov 2028 expected | HER2 positive breast carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06849947 Comparator | Feb 2026 → Jun 2031 expected | breast carcinoma | Yeon Hee Park | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07581834 Background | Jan 2026 → Dec 2031 expected | hormone receptor-positive breast cancer | Fujian Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07071038 Comparator | Oct 2025 → Aug 2026 overdue | breast cancer | Dartmouth-Hitchcock Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07101159 Background | Sep 2025 → Dec 2031 expected | hormone receptor-positive breast cancer | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06486883 Comparator | Jun 2025 → Jan 2027 expected | hormone receptor-positive breast cancer | MedSIR | Recruiting | No outcome recorded |
| Phase 2 | NCT06428396 Comparator | Nov 2024 → May 2027 expected | breast cancer | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06369285 Background | Nov 2024 → Jun 2027 expected | hormone receptor-positive breast cancer | Puma Biotechnology, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06656624 Background | Aug 2024 → Dec 2025 overdue | female breast carcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06179303 Background | Jul 2024 → Mar 2027 expected | female breast carcinoma, hormone receptor-positive breast cancer | University of Washington | Recruiting | No outcome recorded |
| Phase 2 | NCT06075953 Comparator | Feb 2024 → Nov 2028 expected | ductal breast carcinoma in situ | QuantumLeap Healthcare Collaborative | Recruiting | No outcome recorded |
| Phase 2 | NCT06105632 Comparator | Jan 2024 → Jan 2026 overdue | breast cancer | Pfizer | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06001762 Background | Oct 2023 → Jan 2025 overdue | breast carcinoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05872347 Background | Sep 2023 → Dec 2026 expected | metastatic malignant neoplasm in the brain | Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT05949541 Background | Jul 2023 → Jul 2026 overdue | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05983107 Background | Jul 2023 → Jul 2026 overdue | hormone receptor-positive breast cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT05079360 Comparator | Mar 2023 → Mar 2024 | breast cancer | Veru Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT05594095 Background | Dec 2022 → Dec 2025 overdue | female breast carcinoma, hormone receptor-positive breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05463601 Background | Aug 2022 → Jan 2025 overdue | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05431504 Background | Jun 2022 → Dec 2025 overdue | female breast carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05472792 Comparator | May 2022 → Apr 2027 expected | breast cancer | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04985266 Comparator | Mar 2022 → Sep 2027 expected | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | Royal Marsden NHS Foundation Trust | Recruiting | No outcome recorded |
| Phase 2 | NCT04300790 Background | Oct 2020 → Jun 2022 | breast cancer | MedSIR | Completed | No outcome recorded |
| Phase 2 | NCT04460430 Background | Jul 2020 → Nov 2021 | breast cancer | SOLTI Breast Cancer Research Group | Terminated | No outcome recorded |
| Phase 2 | NCT04059484 Comparator | Oct 2019 → Feb 2022 | breast cancer | Sanofi | Terminated | No outcome recorded |
| Phase 2 | NCT04023292 Comparator | Jul 2019 → Jul 2023 | breast neoplasm | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03910712 Background | Jun 2019 → Jun 2022 | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02917005 Background | May 2019 → Dec 2021 | breast cancer | Hamdy A. Azim | Unknown | No outcome recorded |
| Phase 2 | NCT03874325 Background | Apr 2019 → Nov 2020 | hormone receptor-positive breast cancer | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT03659136 Background | Nov 2018 → Aug 2021 | breast cancer | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT04012918 Comparator | Aug 2018 → Aug 2020 | breast cancer | Ain Shams University | Unknown | No outcome recorded |
| Phase 2 | NCT03555877 Background | Mar 2018 → Jul 2022 | breast carcinoma | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 2 | NCT03321981 Background | Jan 2018 → Oct 2022 | breast carcinoma | Merus B.V. | Completed | No outcome recorded |
| Phase 2 | NCT03291886 Background | Sep 2017 → Apr 2019 | breast cancer | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03312738 Background | Sep 2017 → Apr 2022 | female breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03184090 Background | Jun 2017 → Oct 2020 | metastatic malignant neoplasm | MedSIR | Completed | No outcome recorded |
| Phase 2 | NCT03078751 Background | Jun 2017 → Mar 2020 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03024580 Comparator | Mar 2017 → Mar 2020 | breast neoplasm | Brazilian National Cancer Institute | Unknown | No outcome recorded |
| Phase 2 | NCT02646735 Comparator | Dec 2015 → Dec 2019 | breast cancer | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT02592083 Background | Oct 2015 → Feb 2019 overdue | hormone receptor-positive breast cancer | Thomas Hatschek | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02676986 Comparator | Aug 2015 → Dec 2016 | estrogen-receptor positive breast cancer | Queen Mary University of London | Completed | No outcome recorded |
| Phase 2 | NCT02258451 Background | Jun 2015 → Jan 2020 | breast cancer | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT02440230 Comparator | May 2015 → Dec 2021 | breast cancer | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT02291913 Background | Dec 2014 → Jan 2019 | breast cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02213042 Comparator | Oct 2014 → Jun 2020 | breast cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02069093 Background | May 2014 → Mar 2016 | female breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02040857 Background | Jan 2014 → May 2018 | breast cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT01783444 Comparator | Feb 2013 → Jul 2018 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01658176 Comparator | Jan 2013 → Apr 2015 | breast neoplasm | Pfizer | Withdrawn | No outcome recorded |
| Phase 2 | NCT01605396 Background | Jul 2012 → Feb 2014 | breast neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT01654185 Background | Jul 2012 → Jul 2014 | breast cancer | Xichun Hu | Completed | No outcome recorded |
| Phase 2 | NCT01446159 Background | Jun 2011 → Jun 2019 | Her2-receptor negative breast cancer | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT01220128 Background | Apr 2011 → Nov 2014 | breast cancer | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2 | NCT01240941 Background | Feb 2011 → Jun 2012 | breast cancer | Vanderbilt-Ingram Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT01234857 Comparator | Sep 2010 → Oct 2013 | breast cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT01004081 Background | Nov 2009 → Oct 2011 | breast cancer | Biogen | Completed | No outcome recorded |
| Phase 2 | NCT00935558 Comparator | Jul 2009 → May 2012 | breast cancer | Inge Marie Svane | Withdrawn | No outcome recorded |
| Phase 2 | NCT00767520 Comparator | Feb 2009 → Mar 2011 | breast cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT00828854 Background | Oct 2008 → Nov 2009 | estrogen-receptor positive breast cancer | Syndax Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00728949 Comparator | Aug 2008 → Mar 2012 | breast cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00676663 Background | Jun 2008 → Jan 2011 | estrogen-receptor positive breast cancer | Syndax Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00573755 Background | Dec 2007 → Apr 2013 | breast cancer | Mayo Clinic | Terminated | No outcome recorded |
| Phase 2 | NCT00372996 Comparator | Feb 2007 → Sep 2012 | breast cancer | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00240071 Background | Oct 2005 → Mar 2009 | breast cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT00038103 Comparator | Jan 2002 → Mar 2008 | breast cancer | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00031889 Comparator | Aug 2001 → Jun 2002 | prostate cancer | Swiss Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00128843 Comparator | Aug 2001 → Jul 2005 | breast cancer | Spanish Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00684216 Comparator | Apr 2008 → May 2012 | breast cancer | The Netherlands Cancer Institute | Terminated | No outcome recorded |
| Phase 354 trials | ||||||
| Phase 3 | NCT07349069 Comparator | Mar 2026 → Dec 2030 expected | breast cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07400523 Background | Feb 2026 → Feb 2030 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT06585969 Comparator | Jan 2026 | basal-like breast carcinoma, estrogen-receptor positive breast cancer, luminal B breast carcinoma | Danish Breast Cancer Cooperative Group | Withdrawn | No outcome recorded |
| Phase 3 | NCT07174336 Background | Dec 2025 → May 2029 expected | breast cancer, metastatic neoplasm | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT07062965 Comparator | Aug 2025 → Jul 2027 expected | breast cancer | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT07024173 Comparator | Jul 2025 → Dec 2026 expected | female breast carcinoma | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07061717 Comparator | Jul 2025 → Jul 2029 expected | hormone receptor-positive breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07019363 Comparator | Jun 2025 → May 2029 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT06671912 Comparator | Feb 2025 → Nov 2030 | Her2-receptor negative breast cancer, ductal breast carcinoma in situ, estrogen-receptor positive breast cancer, lobular breast carcinoma in situ | Alliance for Clinical Trials in Oncology | Suspended | No outcome recorded |
| Phase 3 | NCT07190443 Comparator | Feb 2025 → Feb 2034 expected | breast cancer | Japanese Foundation for Cancer Research | Recruiting | No outcome recorded |
| Phase 3 | NCT06680921 Comparator | Nov 2024 → Aug 2028 expected | breast cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06380751 Comparator | Aug 2024 → Mar 2029 expected | female breast carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06044623 Background | Apr 2024 → Oct 2028 expected | breast cancer | Region Örebro County | Recruiting | No outcome recorded |
| Phase 3 | NCT05827081 Background | Feb 2024 → Sep 2029 expected | female breast carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06447623 Background | Feb 2024 → Feb 2027 expected | hormone receptor-positive breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05512364 Comparator | Dec 2023 → Nov 2032 expected | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | European Organisation for Research and Treatment of Cancer - EORTC | Recruiting | No outcome recorded |
| Phase 3 | NCT06016738 Comparator | Nov 2023 → Jun 2026 overdue | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | Olema Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05952557 Comparator | Oct 2023 → Mar 2030 expected | breast carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT05894239 Background | Sep 2023 → Dec 2026 expected | breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT05891093 Background | Jun 2023 → May 2028 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05861830 Background | May 2023 → Dec 2025 | female breast carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT05774951 Comparator | Mar 2023 → Apr 2027 expected | breast carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT05645536 Background | Dec 2022 → Jun 2028 expected | breast cancer | Tolmar Inc. | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT05514054 Comparator | Oct 2022 → Oct 2027 expected | breast neoplasm | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05306340 Comparator | Aug 2022 → Jul 2025 overdue | estrogen-receptor positive breast cancer | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05065411 Comparator | Apr 2022 → Oct 2023 | breast cancer | Veru Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT04869943 Comparator | Oct 2021 → Jan 2024 | breast cancer | Veru Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT04961996 Comparator | Aug 2021 → Aug 2025 overdue | breast cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04906395 Background | Jul 2021 → Apr 2026 overdue | female breast carcinoma | Tolmar Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04852887 Comparator | Jun 2021 → Apr 2031 expected | female breast carcinoma | NRG Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT04134598 Comparator | Feb 2021 → Mar 2030 expected | breast cancer | Careggi University Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04584853 Background | Dec 2020 → Oct 2030 expected | female breast carcinoma | Institute of Cancer Research, United Kingdom | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03820830 Background | Aug 2019 → Jul 2026 overdue | breast cancer | ETOP IBCSG Partners Foundation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03778931 Comparator | May 2019 → Aug 2021 | breast cancer | Stemline Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03538171 Comparator | May 2018 → Jul 2021 | breast cancer | Taizhou EOC Pharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03081234 Background | Mar 2018 → Nov 2025 | breast cancer | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT02767661 Background | Jul 2017 → Aug 2023 | breast cancer | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT02947685 Background | Jun 2017 → Oct 2024 overdue | HER2 positive breast carcinoma, estrogen-receptor positive breast cancer | Alliance Foundation Trials, LLC. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02482753 Background | Jul 2015 → Mar 2018 | breast cancer | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02511639 Background | Jul 2014 → Feb 2020 | breast cancer | Veneto Institute of Oncology IRCCS | Completed | No outcome recorded |
| Phase 3 | NCT01674140 Background | Sep 2013 → Dec 2022 overdue | breast cancer | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03176238 Background | Mar 2013 → Jan 2019 | breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01619111 Comparator | Feb 2012 → Jan 2022 | HER2 positive breast carcinoma, Her2-receptor negative breast cancer | University of Ulm | Completed | No outcome recorded |
| Phase 3 | NCT02995772 Comparator | Nov 2011 → Nov 2018 | breast cancer | Dharmais National Cancer Center Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01160211 Background | May 2011 → Mar 2016 | breast neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01272037 Background | Feb 2011 → Feb 2023 overdue | ductal breast carcinoma in situ, invasive breast carcinoma, synchronous bilateral breast carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00863655 Background | Jun 2009 → Dec 2014 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00944918 Comparator | Dec 2008 → Jun 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00688194 Comparator | May 2008 → May 2013 | breast cancer | Gruppo Italiano Mammella (GIM) | Unknown | No outcome recorded |
| Phase 3 | NCT00310180 Background | Apr 2006 → Mar 2018 overdue | breast adenocarcinoma, hormone receptor-positive breast cancer | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00253422 Comparator | Mar 2004 → Nov 2022 | breast cancer | Institute of Cancer Research, United Kingdom | Completed | No outcome recorded |
| Phase 3 | NCT00065325 Comparator | Aug 2003 → Jun 2006 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00525096 Background | Jul 2003 → Dec 2004 | breast cancer | ARCAGY/ GINECO GROUP | Completed | No outcome recorded |
| Phase 3 | NCT00810706 Comparator | Apr 2001 → Nov 2005 | breast cancer | Hellenic Breast Surgeons Society | Terminated | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT03220178 Background | Jul 2017 → Dec 2021 | breast cancer | Palleos Healthcare GmbH | Terminated | No outcome recorded |
| Phase 4 | NCT02467686 Comparator | Jan 2014 → Sep 2017 | — | Irmandade da Santa Casa de Misericordia de Sao Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT01612871 Background | Jun 2012 → Jan 2016 | female breast carcinoma | Institut Claudius Regaud | Completed | No outcome recorded |
| Phase 4 | NCT00649090 Comparator | Mar 2005 → Apr 2007 | breast neoplasm | Pfizer | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT05890287 Background | May 2023 → May 2026 overdue | hormone receptor-positive breast cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| — | NCT01897441 Background | Jun 2013 → Oct 2023 | female breast carcinoma | Albert Einstein College of Medicine | Terminated | No outcome recorded |
| — | NCT01153672 Background | Nov 2010 → Jul 2012 | male breast carcinoma | University of Washington | Completed | No outcome recorded |
| — | NCT00066586 Comparator | Aug 2001 → Nov 2007 | breast cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| — | NCT00200174 Comparator | Jul 1999 → Jul 2003 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 323 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | exemestane | “Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or...” NCT03820830 ↗318“This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1...” NCT01220128 ↗ “Options include tamoxifen (20 mg daily), aromatase inhibitors (letrozole 2.5 mg daily, anastrozole 1 mg daily, or exemestane 25 mg daily), or fulvestrant (500 mg...” NCT07708194 ↗ “Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of...” NCT01446159 ↗ “Endocrine therapy is determined by the doctor, including any kind of letrozole, anastrozole, exemestane, fulvestrant, tamoxifen, toremifene, combined with or without drugs or...” NCT03204734 ↗ “Endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole). Endocrine therapy must be...” NCT03184090 ↗ “Tamoxifen 20 mg daily, or letrozole 2.5 mg daily, or anastrozole 1 mg daily, or exemestane 25 mg daily (male patients will be treated with tamoxifen 20 mg daily) for a total...” NCT03081234 ↗ “Postmenopausal patients: Letrozole (2.5 mg, orally, once daily, for 5 years) or Anastrozole (1 mg, orally, once daily, for 5 years) or Exemestane (25 mg, orally, once daily,...” NCT07153757 ↗ “Subjects will receive standard therapy with an aromatase inhibitor (exemestane, anastrozole, or letrozole), combined with the experimental treatment of abemaciclib and durvalumab” NCT04088032 ↗ “Letrozole 2.5 mg by mouth daily, or anastrozole 1 mg by mouth daily, exemestane 25 mg by mouth daily, tamoxifen 20 mg by mouth daily, for a total duration of at least 60 months.” NCT03078751 ↗ “The physician's choice of endocrine therapy (PCET) is limited to tamoxifen or one of the specified third generation aromatase inhibitors: letrozole, anastrozole, or exemestane.” NCT04961996 ↗ “Endocrine therapy: letrozole (2.5mg daily), anastrozole (1mg daily), exemestane (25mg daily), tamoxifen (20mg daily) or fulvestrant (intramuscular 500mg every 4 weeks)” NCT06585969 ↗ “aromatase inhibitor (letrozole 2.5mg/d PO, anastrazole 1mg/d PO, or exemestane 25mg/d PO)or Selective Estrogen Receptor Modulator (SERM) (tamoxifen 20mg/d PO)” NCT00240071 ↗ “Participants in the switch arm will receive a new prescription for either anastrozole or exemestane at a dose of 1mg or 25mg daily, respectively.” NCT07071038 ↗ “Aromatase inhibitors(Letrozole/Anastrozole/Exemestane, po, qd, specific dose (letrozole 2.5mg/ day; Anastrozole 1mg/ day, Exemestane 25mg/ day)” NCT05594095 ↗ “Patients will receive one of the aromatase inhibitors either anastrozole 1 mg po daily, letrozole 2.5 mg po daily, or exemestane 25 mg po daily” NCT01484041 ↗ “The first cohort patients will receive tremelimumab (3 mg/kg, single infusion) as immune-attractants combined with exemestane (25 mg daily).” NCT02997995 ↗ “Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)” NCT05362760 ↗ “The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.” NCT03910712 ↗ “The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.” NCT04088110 ↗ “oral anastrozole 1 mg per day, exemestane 25 mg per day, or letrozole 2·5 mg per day; ipatasertib and aromatase inhibitor group” PMID 42061370 ↗ May 2026 “The AIs the Investigator could choose from were anastrozole, exemestane, and letrozole and dosing was per product information.” NCT02213042 ↗ “Includes anastrozole 1 mg/day, letrozole 2.5 mg/day, or exemestane 25 mg/day, administered orally once daily for 4 cycles.” NCT07618923 ↗ “Goserelin: 3.6mg, d1, hypodermic injection , q28d\*7 plus exemestane: 25mg, po, qd\*24w, or anastrozole: 1mg, po, qd\*24w” NCT02532400 ↗ “["Letrozole","Anastrozole","Exemestane","Tamoxifen","Leuprolide, or other LHRH agonist (per investigator discretion)"]” NCT04569747 ↗ “Aromatase inhibitor (either letrozole, anastrozole, or exemestane) of investigator's choice given by mouth once daily” NCT01160211 ↗ “the neoadjuvant treatment regimen of trastuzumab dual-target combined with exemestane and palbociclib for 4 cycles.” NCT07300215 ↗ “either Anastrozole 1 mg po daily; Letrozole 2.5 mg po daily, Exemestane 25 mg po daily or Tamoxifen 20 mg po daily” NCT01897441 ↗ “take orally one tablet per day of exemestane 25 mg and one tablet per day of anastrozole placebo daily after meal” NCT00143390 ↗ “Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25mg, or Fulvestrant 0.5g IM on Days 1, 28 (initial: Days 1, 15, 28)” NCT07610720 ↗ “Endocrine therapy including but not limited to fulvestran, tanastrozole, letrozole or exemestane In regular doses” NCT05431504 ↗ “Hemay022 combined with AI (exemestane or letrozole) in the treatment of ER+/HER2+ advanced breast cancer patients” NCT06313983 ↗ “Tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc, selected at the discretion of the investigator.” NCT05983107 ↗ “The endocrine therapy used for the NET in this study will be anastrozole, letrozole, exemestane, or tamoxifen.” NCT07483307 ↗ “physician's choice of endocrine therapy (ET) including fulvestrant, letrozole, anastrozole, and exemestane” NCT06486883 ↗ “Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant.” NCT05949541 ↗ “Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant.” NCT06447623 ↗ “Tamoxifen or aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) combined with trastuzumab” NCT01950182 ↗ “Non-steroidal AIs (anastrozole, letrozole); steroidal AI (exemestane); Fulvestrant or Tamoxifen” NCT02448420 ↗ “premenopausal: tamoxifen or toremifene; postmenopausal: letrozole or anastrozole or exemestane” NCT04383275 ↗ “Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor” NCT06044623 ↗ “Endocrine Therapy: Tamoxifen 20mg, Letrozole 2.5mg, Anastrozole 1mg, or Exemestane 25mg PO qd” NCT02040857 ↗ “Endocrine Therapy: Exemestane (Aromasin®), Letrozole (Femara®), or Anastrozole (Arimidex®)” NCT03846583 ↗ “letrozole oral 2·5 mg/day, anastrozole oral 1 mg/day, or exemestane oral 5 mg/day” NCT07400523 ↗ “Exemestane is formulated as tablets of 25 mg strength for oral administration.” NCT02511639 ↗ “Anastrozole or Exemestane or Letrozole administered orally (physician choice)” NCT04188548 ↗ “exemestane from the 1st to the 21st day of the 21 day cycle: 25mg, oral Q24H” NCT05969184 ↗ “Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)” NCT01619111 ↗ “combined with an aromatase inhibitor (letrozole/anastrozole/exemestane)” NCT06970912 ↗ “Anastrozole 1 mg, letrozole 2.5 mg, or exemestane 25 mg by mouth daily” NCT06218303 ↗ “Exemestane (25 mg orally once daily on day 1 to 28 in a 28 day cycle)” NCT06849947 ↗ “Exemestane: 25 mg once daily on a continuous scheme (tablets, per os)” NCT03079011 ↗ “3. Exemestane 25mg oral administration every day (1 cycle = 4 weeks)” NCT06837792 ↗ “Anastrozole 1mg/day p.o,Exemestane 25mg/day,Letrozole 2.5mg/day p.o.” NCT01924078 ↗ “Exemestane: 25 mg, orally, once daily (continuous), every 28 days” NCT05861830 ↗ “Chidamide+ exemestane/Fulvestrant/Letrozole/Anastrozole/Tamoxifen” NCT05890287 ↗ “MTOR inhibitor + anti-estrogen therapy (everolimus + exemestane)” NCT04965688 ↗ “ANASTRAZOLE, ARIMIDEX, AROMASINE, EXEMESTANE, FEMARA, LETROZOLE” NCT03624244 ↗ “letrozole 2.5 mg, anastrozole 1 mg, or exemestane 20 mg PO qd” NCT06145308 ↗ “Any brand of letrozole, anastrozole or exemestane may be used” NCT02603679 ↗ “Exemestane: 25 mg/day on a continuous dosing schedule” NCT03778931 ↗ “Endocrine therapy (letrozole/anastrozole/exemestane)” NCT07005557 ↗ “Neratinib plus Fulvestrant, Exemestane or Tamoxifen” NCT04460430 ↗ “tamoxifen, Letrozole, Anastrazole, Exemestane, etc.” NCT04023292 ↗ “Exemestane 25 mg (tablet) is administered PO daily” NCT00935558 ↗ “25 mg of exemestane tablet by mouth once daily or” NCT06369285 ↗ “* AI: Anastrozole, Letrozole or Exemestane” NCT05826964 ↗ “Exemestane Tablets: 25mg, 1 time /d, oral” NCT06656624 ↗ “Exemestane, given per os, 25 mg daily” NCT05297617 ↗ “anastrozole, letrozole, or exemestane” NCT05894239 ↗ “Letrozol or Anastrozol or Exemestane” NCT02592083 ↗ “Exemestane , 25mg, orally once daily” NCT02767661 ↗ “Exemestane , 25mg, orally once daily” NCT05411380 ↗ “Aromasin® (exemestane) 25 mg/day PO” NCT00828854 ↗ “Etoposide, Exemestane, Floxuridine” NCT02788201 ↗ “Exemestane 25mg once a day orally” NCT02910050 ↗ “Exemestane：Administered by oral” NCT05872347 ↗ “Exemestane25mg once daily” NCT07527806 ↗ “letrozole or exemestane” NCT01654185 ↗ “exemestane (Aromasin®)” NCT00508586 ↗ “Aromasin (exemestane)” NCT01176916 ↗ “exemestane” NCT03321981 ↗ “Exemestane” NCT07596212 ↗ “Exemestane” NCT02995772 ↗ “Exemestane” NCT03948568 ↗ |
| Known as | Aromasin | “A Phase 4, Open-Label Exemestane Adjuvant Safety Surveillance Program: Adjuvant Exemestane (Aromasin) Treatment Following Previous Treatment With Tamoxifen in Postmenopausal...” NCT00649090 ↗8“aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone...” NCT04012918 ↗ “Endocrine Therapy: Exemestane (Aromasin®), Letrozole (Femara®), or Anastrozole (Arimidex®)” NCT03846583 ↗ “A commercial supply of exemestane (Aromasin) will be provided.” NCT00261027 ↗ “IM or Oral Exemestane (Aromasin) in Postmenopausal Women” NCT00040014 ↗ “Aromasin® (exemestane) 25 mg/day PO” NCT00828854 ↗ “exemestane (Aromasin®)” NCT00174343 ↗ “exemestane (Aromasin®)” NCT00508586 ↗ |
| Known as | Aromasin (exemestane) | “Aromasin (exemestane)” NCT00240071 ↗1“Aromasin (exemestane)” NCT01897441 ↗ |
| Known as | Aromasin, exemestane, Pfizer | “Aromasin®, exemestane, Pfizer” NCT00935558 ↗ |
| Known as | Baby Exemestane | “Randomized Double Blind Phase II Trial of Baby Exemestane vs Baby Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.” NCT06364267 ↗ |
| Known as | BabyEXE | “The purpose of the study is to to compare low dose of exemestane (babyexe) versus low dose of tamoxifen (babytam) in terms of change of quality of life from baseline to 12 months.” NCT06364267 ↗ |
| Known as | EXE | “We hypothesized that exemestane (EXE) would reduce mammographic breast density and have unique effects on biomarkers of bone and lipid metabolism.” PMID 21221773 ↗ Jan 2011 |
| Known as | Exemestane (Aromasin) | “Exemestane (Aromasin)” NCT06218303 ↗ |
| Known as | Exemestane Tablets | “Drug: Exemestane Tablets” NCT04906395 ↗ |
| Known as | Exemestano | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200374 ↗ |
| Known as | FCE-24304 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200374 ↗ |
| Known as | NSC-758907 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200374 ↗ |
| Known as | PNU-155971 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200374 ↗ |
| Action | Inhibit | “Hormone therapy using exemestane or tamoxifen may fight cancer by blocking the uptake of estrogen.” NCT00002777 ↗1“Cytochrome P450 19A1 inhibitor” CHEMBL1200374 ↗ |
| Modality | Small molecule | “the steroidal aromatase inactivator exemestane versus the antiestrogen tamoxifen” PMID 18794551 ↗ Sep 2008 |
| Route | Oral | “Patients were randomly assigned to receive exemestane 25 mg or tamoxifen 20 mg orally once daily until disease progression or unacceptable toxicity occurred.” PMID 18794551 ↗ Sep 2008 |
| Target | CYP19A1 | “Cytochrome P450 19A1 inhibitor” CHEMBL1200374 ↗ |